Helius Medical Technologies, Inc. to Release Third Quarter 2021 Financial Results on November 10, 2021
November 01 2021 - 7:05AM
Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the
“Company”), a neurotech company focused on neurological wellness,
today announced that the Company will release its third quarter
2021 financial results on Wednesday, November 10, 2021, after the
market closes.
Dane C. Andreeff, President and Chief Executive
Officer, and Jeffrey S. Mathiesen, Chief Financial Officer, will
host a conference call to discuss the results and provide a
business update as follows:
Date: |
|
Wednesday, November 10, 2021 |
Time: |
|
5:00 p.m. Eastern Time |
Toll free (U.S.): |
|
(844) 348-4652 |
International: |
|
(213) 358-0895 |
Conference ID: |
|
9388362 |
Webcast: |
|
https://edge.media-server.com/mmc/p/sbbrhapy |
|
|
|
A replay of the call will be available for one
week at (855) 859-2056 (U.S.) or (404) 537-3406 (international).
The conference ID for the replay is 9388362. The webcast will be
archived under the Newsroom section of the Company’s investor
relations website.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a leading
neurotech company in the medical device field focused on neurologic
deficits using non-implantable platform technologies that amplify
the brain’s ability to compensate and promote neuroplasticity,
aiming to improve the lives of people dealing with neurologic
diseases.
The Company’s first commercial product is the
Portable Neuromodulation Stimulator (PoNS®). For more information,
visit www.heliusmedical.com.
About the
PoNS® Device and PoNS
Therapy
The Portable Neuromodulation Stimulator (PoNS®)
is an innovative non-surgical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to provide treatment of gait deficit. The PoNS® device
is indicated for use in the United States as a short-term treatment
of gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. It is authorized for sale in Canada as a
class II, non-implantable, medical device intended as a short-term
treatment (14 weeks) of gait deficit due to mild and moderate
symptoms from MS, and chronic balance deficit due to
mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used
in conjunction with physical therapy. The PoNS® is an
investigational medical device in Australia (“AUS”) and is
currently under premarket review by the AUS Therapeutic Goods
Administration.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024